Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)

Summary

Alzheimer's disease (AD) is usually associated with aging, age being the principal identified risk factor. However, younger subjects also develop AD and the prevalence of early onset AD is unknown. It is estimated that about 30 000 subjects develop symptoms of AD before the age of 65 in France. There is evidence that early onset AD differs from AD in older patients. In particular, clinical and neuroimaging studies suggest early involvement of neocortical brain regions and their functions in early onset AD, while mediotemporal areas and memory might be more involved in late onset AD. These differences could partly explain the atypical clinical and imaging features of younger patients, the diagnostic difficulties in these patients and the specific problems related to medical care of this age group. The present study uses a multidisciplinary approach with longitudinal followup in order to establish the impact of age on the clinical and neuroimaging picture of sporadic AD in a multicentric setting. Another aim of the project is to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.

Conditions

• Alzheimer's Disease

Interventions

BIOLOGICAL

Clinic and neuropsychologic evaluation

evaluation at the inclusion and 18 months after

RADIATION

MRI

intervention at the inclusion and 18 months after

PROCEDURE

PET

18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.

BIOLOGICAL

Apolipoprotein E genotyping

genotyping at the inclusion

BIOLOGICAL

Study of cerebrospinal fluid

intervention at the inclusion

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille

  lead OTHER

Principal Investigators

• mathieu ceccaldi · Assistance Publique - Hôpitaux de Marseille

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

45 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2009-10-31

Primary Completion

2016-09-30

Countries

• France

Study Locations